Q1 2025 Earnings Call Transcript May 6, 2025 AdaptHealth Corp. reports earnings inline with expectations. Reported EPS is ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

Pia Eaves; Vice President of Investor Relations & Strategy; Arcus Biosciences Inc. Terry Rosen; Chairman of the Board, Chief Executive Officer, Co-Founder; Arcus Bio ...

The approvals of Onpattro, Givlaari, Oxlumo, and Leqvio combined with several partnerships have bolstered Alnylam's cash balance, and the company concluded fiscal 2024 with $2.69 billion in cash, cash ...

The Oncology Institute's stock surged 900% amid insider buying, despite cash burn, unprofitability, and potential need for ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies of $58 ...

Operator: Good afternoon, and welcome to Huron Consulting Group’s webcast to discuss Financial Results for the First Quarter ...

ONT, which was IP Group’s largest holding at end-2024 (13% of portfolio value), offers a new generation of nanopore-based sensing technology, enabling the real-time, high-performance, accessible and ...